Ascendis Pharma/$ASND

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Ascendis Pharma

Ascendis Pharma AS is a biopharmaceutical company that applies its TransCon technology platform to make a meaningful difference for patients. The firm's product pipeline includes Endocrinology and Oncology which includes TransCon PTH, TransCon CNP, and others. It operates in North America, Europe, and Rest of the world and derives the majority of its revenue from North America.

Ticker

$ASND
Sector
Primary listing

Employees

1,017

Headquarters

Hellerup, Denmark

Ascendis Pharma Metrics

BasicAdvanced
$13B
-
-$5.30
0.39
-

What the Analysts think about Ascendis Pharma

Analyst ratings (Buy, Hold, Sell) for Ascendis Pharma stock.

Bulls say / Bears say

Ascendis Pharma’s Q2 2025 revenue of EUR 158.05 million exceeded analyst expectations of EUR 142.38 million, driven by strong sales of YORVIPATH and SKYTROFA, resulting in a 2.9% stock gain post-announcement (Reuters)
YORVIPATH (TransCon PTH) generated EUR 103.0 million in Q2 2025, with approximately 3,100 unique patient enrollments and over 1,500 U.S. prescribers, demonstrating robust commercial adoption (Reuters)
The FDA has accepted the NDA for TransCon CNP (navepegritide) for priority review, granting a PDUFA goal date of November 30, 2025, which, if approved, could add a third high-value medicine to Ascendis’s portfolio (Ascendis Pharma)
Ascendis Pharma remains unprofitable, reporting a Q2 2025 loss of EUR 0.82 per share despite revenue growth, highlighting ongoing challenges in reaching profitability (Reuters)
Selling, general, and administrative expenses surged to EUR 107.6 million in Q2 2025 from EUR 74.3 million a year earlier, underscoring increasing burn rates from continued commercial expansion (Reuters)
TransCon CNP’s U.S. approval remains uncertain as its NDA is under FDA priority review with a PDUFA date set for November 30, 2025, introducing significant execution risk for the company’s growth disorders franchise (Ascendis Pharma)
Data summarised monthly by Lightyear AI. Last updated on 7 Oct 2025.

Ascendis Pharma Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

Ascendis Pharma Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $ASND

Sign up or log in to buy
Capital at risk
Market closedADR

Upcoming events

No upcoming events
FAQs